Company Overview
from 2021 or 2022 only)
Name
Location
Website
 1-2 sentence overview
 Any parent companies; (for
example: Atia Vision is a portfolio
company of Shifamed, LLC)
 Company size: Are they
small/startup or global with 100+
employees?
 Any comments about where they
are looking to expand or grow
 A statement about their goals that
we can parrot back to them in the
outreach
Samsara Vision
Far Hills, NJ
www.samsaravision.com
T: 408.872.9393    Joined as CEO in July 2020
F: 408.872.9395    ~ 20 years of ophthalmology
info@samsaravision.com
 Focused on bringing vision and
freedom back to patients with late-
stage AMD and untreatable retinal
disorders
 Specialty medical device company
 Research, development,
manufacture, and marketing of
proprietary implantable ophthalmic
devices and technologies
2022 OIC Presenter
Key People (Up to 2 people)
Name, position
Email
 Current role, years in role
 Past companies/positions
 Key/recent achievements
To include: decision makers CEO, Heads
of Business Development, Heads of Sales
and Marketing;
Do not need: CFOs, PR companies
First name Last name
President & CEO
email goes here
business experience
 Previously at Johnson & Johnson
Vision/Janssen (5 years, VP WW
Customer Experience and Ocular
Surface Disease and Commercial
Strategy Leader)
 Previous Alcon, a division of
Novartis (14 years, sales and
marketing)
First name Last name
VP Worldwide Marketing
email goes here
Products (top products)
 2-3 sentence/bullet overview of
product line
 Names of the top 2 products
and one sentence statement
about what they are
 How many products are
commercial?
 Stage of product line
(commercial, clinical trial, early
stage)
 Which products have FDA?
 One picture of their top
technology
Do not need: full portfolio with every
full product description – better to
include a link to the product webpage
so we can review as needed
SING IMT
An Implantable Miniature
Telescope that has demonstrated
significant vision and quality of life
improvements in patients with late Samsara Vision Seeks
stage AMD
 Launching in Europe and
select global markets.
 IMT is already FDA approved
in the US
CONCERTO trial in US
(PMA-Supplement trial)
Two multi-year clinical studies
have been conducted to evaluate
the safety and efficacy of the
Implantable Miniature Telescope:
the IMT-002 pivotal safety and
efficacy study and the IMT-002-
Financials News – ( 1 – 2 recent headlines
 Total investment  What is the company publishing
 Recent investments about recent events/milestones?
or fundraising  Any recent clinical trial results or
actives trials initiated?
 Potential strategic partnerships,
acquisitions or licensing deals
 Presenting at any conferences?
 Especially anything in the last 3-6
months; no later than 2 years old
 Who are they hiring – what have the
posted on their career board (can
just be a summary total number of
roles looking to fill and type)
 Privately held Jul 11, 2022 - Samsara Vision Announces
 Planned to go public First US Surgeries of the SING IMT
but did not yet (Smaller-Incision New-Generation
Implantable Miniature Telescope), for
Age-Related Macular Degeneration as
$31 Million IPO, Nov part of the CONCERTO Study
2021
Apr 20, 2022 - Samsara Vision to Initiate
Samsara Vision a U.S. PMA Supplemental Study of the
Downsizes Proposed SING IMT™, a New-Generation
IPO by 40% to $15M, Technology for Age-Related Macular
Mar 2022 Degeneration
Mar 10, 2022 - Samsara Vision Awarded
NUB Status 1 Reimbursement
Designation for SING IMT
May 25, 2021 - Samsara Vision Reports
That Patients Blinded by Macular
 Joined in January 2021 LTM long-term monitoring safety Degeneration Benefit from Milestone in
 18 years commercial, study. Implant Technology
ophthalmology marketing and
sales experience at Novartis
Pharmaceuticals and Alcon
Laboratories
 Most recently he held roles in
marketing and sales leadership for
Novartis Retina, where he was
part of the build and launch of the
newest Anti-VEGF for wet AMD.